BPC-157 typical research dosing
Across the available literature, BPC-157 is most commonly administered at 250–500 mcg per dose, 2 time(s) per day, via subcutaneous injection. Researchers commonly report subcutaneous injection near the site of interest. Doses in animal studies typically scale to 2.5–10 mcg/kg.
BPC-157 unit-conversion table
The number of insulin-syringe units you draw depends on how much bacteriostatic water you used to reconstitute the vial. The table below shows units to draw on a U-100 syringe for a 5 mg BPC-157 vial at common reconstitution volumes.
| Diluent (mL) | Concentration | 250 mcg | 375 mcg | 500 mcg |
|---|---|---|---|---|
| 1 mL | 5000 mcg/mL | 5.0 units | 7.5 units | 10.0 units |
| 2 mL | 2500 mcg/mL | 10.0 units | 15.0 units | 20.0 units |
| 3 mL | 1667 mcg/mL | 15.0 units | 22.5 units | 30.0 units |
| 5 mL | 1000 mcg/mL | 25.0 units | 37.5 units | 50.0 units |
BPC-157 cycle length
Most reported BPC-157 protocols run 4 weeks on, then 2 weeks off. Cycles are used in research to study washout, receptor sensitivity, and to re-baseline endogenous signaling before re-introducing the compound.
BPC-157 half-life and timing
BPC-157 has a half-life of approximately 4 hours. This influences dose frequency: shorter half-lives often require multiple doses per day to maintain steady-state levels, while longer half-lives can be dosed less frequently.